Clinical trials: TACE, completed
Hepatocellular Carcinoma
A Trial of Adjuvant Transarterial Chemoembolization (TACE) for Preventing Tumor Recurrence After Liver Resection
The aim of this study is to analyze the therapeutic effect of adjuvant TACE after resection.Patients receiving curative resection (R0) were randomized to postoperative TACE group and no TACE group.
- Trial name
- NCT00820053
- Testing
- epirubicin and lipiodol
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Liver Cancer
DEB-TACE Treatment in 367 Liver Cancer Patients
Introduction:The drug-eluting beads transarterial chemoembolization (DEB-TACE) is introduced to better improve efficacy and reduce the systemic toxicity in liver cancer patients on account of its higher intratumoral…
- Trial name
- NCT03317483
- Volunteers
- 367 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma, Hepatoma
Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma
This study will combine two therapies to treat patients with unresectable hepatocellular carcinoma; sorafenib, and drug eluting beads delivered intra-arterially.
- Trial name
- NCT00844883
- Testing
- sorafenib, LC Bead-TACE
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yale University
Unresectable Colorectal Liver Metastasis
Transarterial Chemoembolization by Hepasphere Microspheres for the Treatment of Unresectable Colorectal Liver Metastasis
Colorectal cancer is the third most frequently diagnosed cancer and the third leading cause of cancer related deaths in Taiwan. Of the 10,248 new colorectal patients diagnosed each year approximately 60% will develop liver…
- Trial name
- NCT03264716
- Testing
- HepaSphere TACE (transarterial chemoembolization)
- Where
- Taiwan
- Volunteers
- 5 people
- Sponsor
- National Taiwan University Hospital
Hepatocellular Carcinoma
Sorafenib Chemoembolization Evaluation Controlled Trial
This prospective, multicenter, randomized, controlled study aims to evaluate the efficacy and safety of sorafenib combined with transarterial chemoembolization (TACE) in advanced hepatocellular carcinoma (HCC) patients compared…
- Trial name
- SELECT (NCT01906216)
- Testing
- Sorafenib, TACE
- Where
- China
- Volunteers
- 199 people
- Sponsor
- Air Force Military Medical University, China
Hepatocellular Carcinoma
Comparison Study of Transarterial Chemoembolization and Percutaneous Ethanol Injection for Multiple, Small HCCs
The purpose of this study is to choose the preferred treatment modality for multiple, small hepatocellular carcinomas.
- Trial name
- NCT00357474
- Testing
- Transarterial chemoembolization, Percutaneous ethanol injection therapy
- Where
- South Korea
- Volunteers
- 22 people
- Sponsor
- Seoul National University Hospital
Carcinoma, Hepatocellular
A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).
This study will look at whether our drug (sorafenib) in combination with chemotherapy delivered directly into your tumor using beads (DC Bead) will slow the progression of the disease.
- Trial name
- NCT00855218
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 107 sites in United States, Australia and 11 more
- Volunteers
- 307 people
- Sponsor
- Bayer
Unresectable Hepatocellular Carcinoma, Undergoing Chemoembolization and Radioembolization
TACE Study-Liver Embolization Perfusion (VGH Radiology LIU)
The purpose of this research study is to evaluate the quantitative information of utilizing C-arm systems in liver tumor care in hopes this potential clinical combination of imaging could aid in diagnosis and evaluation of tumor…
- Trial name
- TACE (NCT02093104)
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of British Columbia
Hepatocellular Carcinoma
Pharmacological Manipulation of Intrahepatic Arterial Blood Flow in HCC
Dr Rajan is investigating a new method to improve local treatment of liver cancer. There is evidence that a drug, norepinephrine (NE), has the ability to shrink down normal liver blood vessels, but leave tumor vessels wide open.
- Trial name
- NCT02472249
- Testing
- CT perfusion, Norepinephrine intra-arteriel/hepatic
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University Health Network, Toronto
Liver Cancer, Transcatheter Arterial Chemoembolization
Effectiveness of Positioning on Back Pain After TACE Among Patients With HCC
Changing patients' position in the bed after TACE can decrease the level of back pain without increasing the amount of bleeding and hematoma,bring patients some comfort and relieving abdominal bloating, increase patients'…
- Trial name
- NCT03784469
- Testing
- Changing body position in bed
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- National Taiwan University Hospital
Hepatocellular Carcinoma (HCC)
TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma
This study investigates the clinical efficacy and safety of transarterial chemoembolization (TACE) combined with the immune agent nivolumab compared to TACE alone for treating hepatocellular carcinoma (HCC).
- Trial name
- NCT07053202
- Testing
- Nivolumab, Transarterial Chemoembolization (TACE)
- Where
- China
- Volunteers
- 140 people
- Sponsor
- The First Hospital of Hebei Medical University
Hepatocellular Carcinoma
TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma
Most hepatocellular carcinoma (HCC) are found in the intermediate or advanced stage. The patients lose the opportunity of curative surgical resection.
- Trial name
- NCT06232759
- Testing
- Transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma
Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion
To evaluate and compare the efficacy and safety of sorafenib versus trans-arterial chemoembolization plus external beam radiation therapy in patients with hepatocellular carcinoma invading major intrahepatic vessels
- Trial name
- START (NCT01901692)
- Testing
- TACE+External beam RT, Sorafenib
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Asan Medical Center
Carcinoma, Hepatocellular
Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China
This study is to obtain the characteristics and treatment pattern of the unresectable HCC patients who are candidates for systemic therapy and in whom a decision to treat with sorafenib from early stage of TACE treatment course…
- Trial name
- SUCCESS (NCT01839630)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- China
- Volunteers
- 302 people
- Sponsor
- Bayer
HCC, Transarterial Chemoembolization
A New Conception About Individualized Treatment Allocation for HCC
The current guidelines on hepatocellular carcinoma (HCC) aimed to build effective prognostic stratification strategies to guide therapeutic allocation; however, the current guidelines did not consider the simultaneous comparison…
- Conditions
- HCC, Transarterial Chemoembolization, Resection
- Trial name
- PTA4HCC (NCT06008548)
- Testing
- TACE
- Volunteers
- 4,991 people
- Sponsor
- Tang-Du Hospital
Hepatocellular Carcinoma, HCC
Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver Transplant
This study will compare stereotactic body radiation therapy (SBRT) to trans-arterial chemoembolization (TACE) as a bridging strategy for patients with HCC undergoing orthotopic liver transplantation.
- Trial name
- SBRTvsTACE (NCT02182687)
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Trans-Arterial Chemoembolization (TACE), Doxorubin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Lahey Clinic
Hepatocellular Carcinoma, Face Cancer
Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the 6th most common cancer and the third most frequent cause of cancer death worldwide. Hepatic resection (HR) has been the standard treatment modality for HCC aiming at clinical cure.
- Trial name
- NCT01833299
- Testing
- TACE-Sorafenib group, TACE
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University
Liver Cancer
Chemoembolization Using Doxorubicin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing.
- Trial name
- NCT00293397
- Testing
- Drug-eluting beads loaded with doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yale University
Liver Cancer, Metastatic Cancer
Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor.
- Trial name
- NCT00003907
- Testing
- cisplatin, doxorubicin, mitomycin
- Where
- 37 sites in United States
- Volunteers
- 50 people
- Sponsor
- Eastern Cooperative Oncology Group
Hepatocellular Cancer
HCC Patient Preferences in Japan
This non-interventional cross-sectional online survey will evaluate preferences among patients with self-reported HCC. The survey will ask patients to express their preferences regarding descriptions of HCC treatments, which will…
- Trial name
- NCT02616692
- Testing
- Hepatocellular Cancer (HCC) treatments including oral anti-cancer therapy [Nexavar (Sorafenib, BAY43-9006)]
- Where
- Japan
- Volunteers
- 120 people
- Sponsor
- Bayer